, /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce its participation in the 2024 International Symposium on ALS/MND, to be held December 6-8, 2024, in Montreal, Canada.
During the event, NeuroSense will present the latest findings from its Phase 2b PARADIGM trial of PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).
Key Presentations at the Symposium:
- Prof. Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and the Julieanne Dorn Professor of Neurology at Harvard Medical School, will present the latest clinical outcomes from the PARADIGM trial. As a globally recognized leader in ALS research, Prof. Cudkowicz’s insights into PrimeC’s potential to improve patient outcomes are highly anticipated.
- Dr. Cristian Lunetta, a renowned neurologist and Director of Department of Neuromotor Rehabilitationand ALS Unit of Istituti …